ArticleDigital health
Survival prediction of anaplastic large cell lymphoma-anaplastic lymphoma kinase positive: Based on an ensemble machine learning model.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.British journal of haematology · 2026Review
- Integrative Multiomics Analysis Reveals a Cancer Stem Cell-Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Anaplastic large cell lymphoma-anaplastic lymphoma kinase (ALCL-ALK) positive is a rare subtype of peripheral T-cell lymphoma with generally favorable prognosis but marked clinical heterogeneity. Due to limited research and complex prognostic factors, accurately predicting survival outcomes remains a clinical challenge. Methods: This retrospective cohort study extracted data on 473 patients diagnosed with ALCL-ALK positive between 2016 and 2021 from the Surveillance, Epidemiology, and End Results (SEER) database. A multi-algorithm ensemble machine-learning framework was constructed. The performance of each model combination was systematically evaluated using the area under the curve (AUC) and concordance index, and the least absolute shrinkage and selection operator (LASSO) + Cox proportional hazards model via componentwise likelihood-based boosting (CoxBoost) combination was selected as the optimal model. Feature selection and survival prediction were performed, and model performance was validated using receiver operating characteristic curves and calibration plots. Results: Six key prognostic variables were identified: age, marital status, Ann Arbor stage, radiotherapy, lung metastasis, and primary site. The LASSO + CoxBoost model demonstrated good discriminative ability, calibration, and effective risk stratification in both training and validation set. The AUC at 1, 3, and 5 years were 0.894, 0.829, and 0.862 in the training set, and 0.733, 0.773, and 0.881 in the validation set. Kaplan-Meier survival curves revealed significantly longer overall survival in the low-risk group compared to the high-risk group ( Conclusion: This study is the first to construct a survival prediction model for ALCL-ALK positive using a multi-algorithm ensemble strategy. The model offers a practical tool for individualized risk assessment and may aid in optimizing clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.